araag2/HINT huggingface dataset:
Clinical trial NCT02148120 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: beclometasone dipropionate 100 µg + formoterol fumarate 6 µg, beclometasone dipropionate 200 µg + formoterol fumarate 6 µg, placebo
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)COC(=O)CC)[C@@]1(C)C[C@H](O)[C@@]1(Cl)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient's written informed consent obtained prior to any study-related procedures.

          -  Male or female aged between 18 and 65 years inclusive;

          -  Evidence for "partially controlled" or "uncontrolled" asthma;

          -  Medium daily dose of previous inhaled corticosteroids (ICS) treatment;

          -  FEV1 between 60% and 85% of the predicted normal values;

          -  A documented positive response to the reversibility test;

          -  Non-smokers or ex-smokers;

          -  A cooperative attitude and ability to be trained in the proper use of a DPI.

        Exclusion Criteria:

          -  Pregnant or lactating women and all women physiologically capable of becoming pregnant
             not willing to use at least one acceptable method of contraception.

          -  Significant seasonal variation in asthma occurring or expected to occur during study
             participation;

          -  History of near fatal asthma, brittle asthma, accident and Emergency treatment or
             hospitalisation for asthma exacerbation in Intensive Care Unit within 1 year before
             screening;

          -  Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks
             preceding the screening;

          -  Diagnosis of Chronic Obstructive Pulmonary Disease;

          -  History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency;

          -  Diagnosis of restrictive lung disease;

          -  Patients treated with oral or parenteral corticosteroids in the previous 8 weeks;

          -  Intolerance or contra-indication to treatment with beta2-agonists and/or inhaled
             corticosteroids;

          -  Allergy, sensitivity or intolerance to study drugs or excipients;

          -  Patients who received any investigational drug within the last 8 weeks before the
             screening;

          -  Patients taking any of the non-permitted concomitant medication;

          -  Subjects unlikely to comply with the study protocol;

          -  Any clinically relevant abnormal value or physical finding at screening;

          -  Significant medical history;

          -  Abnormal and clinically significant 12-lead electrocardiogram;

          -  Patients with low compliance of QVAR intake.
Clinical trial NCT02149420 (phase 2, status: completed)
Conditions: primary sjögren's syndrome
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: vay736, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        INCLUSION CRITERIA:

          -  Fulfilled revised European US consensus criteria for pSS

          -  ESSDAI value ≥ 6

          -  Elevated serum titers at screening of ANA (≥ 1:160)

          -  Seropositive at screening for anti-SSA and/or anti-SSB antibodies

          -  Stimulated whole salivary flow rate at screening of > 0 mL/min

        EXCLUSION CRITERIA:

        - Prior or previous use of (specific dosages and intervals prior to study start may apply):
        B-cell depleting therapy (e.g., rituximab), Prednisone, anti-BAFF mAb, CTLA4-Fc Ig
        (abatacept), anti-TNF-α mAb, cyclophosphamide, azathioprine and medications known to cause
        dry mouth.

        Hydroxychloroquine or methotrexate in a consistent dose for ≥ 3 months prior to
        randomization is allowed

          -  Active or recent history of clinically significant infection

          -  Vaccination within 2 month prior to study

          -  History of primary or secondary immunodeficiency
Clinical trial NCT02159365 (phase 2, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: elotuzumab, lenalidomide, dexamethasone
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F
Eligibility criteria:

        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2

          -  Documented evidence of active multiple myeloma:

               -  Newly diagnosed, not candidate for transplant

               -  Relapsed/refractory who have received up to 3 prior lines of therapy

          -  Prior Lenalidomide exposure is permitted only if the following criteria are fulfilled:

               -  Not refractory to prior Lenalidomide which is defined as no progression while
                  receiving Lenalidomide or within 60 days of last dose of Lenalidomide

               -  Subject did not discontinue Lenalidomide due to a Grade ≥3 related adverse event
                  (AE)

        Exclusion Criteria:

          -  Target Disease Exceptions

               -  Plasma cell leukemia

               -  Monoclonal gammopathy of undetermined significance (MGUS)

               -  Smoldering Myeloma

          -  Primary amyloidosis

          -  Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes
             (POEMS) syndrome
Clinical trial NCT02161419 (phase 2, status: terminated)
Conditions: small cell lung carcinoma
ICD codes: D02.20, D02.21, D02.22
Drugs: roniciclib (bay1000394), placebo
SMILES: C[C@@H](O)[C@@H](C)OC1=C(C=NC(NC2=CC=C(C=C2)[S@](=N)(=O)C2CC2)=N1)C(F)(F)F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects aged ≥18 years (or country-specific legal age of maturity, if
             >18 years)

          -  Histologically or cytologically confirmed (extensive-stage disease) ED SCLC (small
             cell lung cancer)

          -  At least 1 solid tumor lesion measurable by computer tomography (CT) scan or magnetic
             resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1

        Exclusion Criteria:

          -  Prior systemic anticancer therapy for SCLC (including previous therapy with a
             cyclin-dependent kinase [CDK] inhibitor)
Clinical trial NCT02161718 (phase 2, status: completed)
Conditions: schizophrenia, alcohol use disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F10.94, F10.980, F10.982, F10.988, F10.99, F10.959, F10.96
Drugs: samidorphan + olanzapine (alks 3831), placebo + olanzapine
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2, CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2
Eligibility criteria:

        Inclusion Criteria:

          -  Has a BMI between 18.0 and 40.0 kg/m2, inclusive

          -  Has a diagnosis of schizophrenia

          -  Has a diagnosis of alcohol use disorder (AUD)

          -  Has experienced an acute exacerbation of schizophrenia within the past 6 months

          -  Additional criteria may apply

        Exclusion Criteria:

          -  Is pregnant or breastfeeding

          -  Had first lifetime psychotic episode less than 1 year before screening or has
             experienced only a single lifetime psychotic episode

          -  Has a known or suspected intolerance, allergy, or hypersensitivity to olanzapine

          -  Has current or pending legal charges with the potential for incarceration

          -  Has a positive drug screen for opiates

          -  Additional criteria may apply
Clinical trial NCT02162719 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: ipatasertib, paclitaxel, placebo
SMILES: [H][C@](CNC(C)C)(C(=O)N1CCN(CC1)C1=NC=NC2=C1[C@]([H])(C)C[C@@]2([H])O)C1=CC=C(Cl)C=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented triple-negative adenocarcinoma of the breast that is
             inoperable locally advanced or metastatic and is not amenable to resection with
             curative intent

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Availability of a representative formalin-fixed, paraffin-embedded (FFPE) tumor
             specimen, required prior to randomization

          -  Measurable disease, according to the RECIST v1.1

          -  Adequate hematologic and organ function within 14 days before the first study
             treatment

          -  For female participants of childbearing potential, agreement (by both participant and
             partner) to use an effective form of contraception for the duration of the study and
             for 6 months after last dose of study treatment

        Exclusion Criteria:

          -  Any previous therapy, including chemotherapy or hormonal or targeted therapy, for
             inoperable locally advanced or metastatic triple-negative adenocarcinoma of the
             breast. Participants may have received prior neoadjuvant or adjuvant chemotherapy
             and/or radiation treatment for locally advanced triple negative adenocarcinoma,
             provided all treatments were completed greater than or equal to (>/=) 6 months prior
             to Cycle 1 Day 1. Locally recurrent disease must not be amenable to resection with
             curative intent

          -  Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1

          -  Known Human Epidermal Growth Factor Receptor 2 (HER2) positive, erythrocyte receptor
             (ER) positive, or progesterone receptor (PR) positive breast cancer

          -  Previous therapy with Akt, PI3K, and/or mTOR inhibitors

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 30 days
             prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during
             the course of the study

          -  Known presence of the brain or spinal cord metastasis, as determined by computed
             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening or
             prior radiographic assessments
Clinical trial NCT02163993 (phase 2, status: completed)
Conditions: migraine headache
ICD codes: G43.B1, G43.D1, G43.B0, G43.D0, G43.A1, G43.411, G43.419
Drugs: galcanezumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participants with a history of migraine of at least 1 year prior to enrollment.

          -  Migraine onset prior to age 50.

        Exclusion Criteria:

          -  Current enrollment in, or discontinuation within the last 30 days from, a clinical
             trial involving any investigational drug or device.

          -  Current use or any prior exposure to any CGRP antibody, any antibody to the CGRP
             receptor, or antibody to nerve growth factor (NGF).

          -  History of migraine subtypes including hemiplegic migraine, ophthalmoplegic migraine,
             and basilar-type migraine.

          -  Have a history or presence of other medical illness that indicates a medical problem
             that would preclude study participation.

          -  Failure to respond to more than two adequately dosed effective migraine prevention
             treatments.

          -  Evidence of significant active psychiatric disease, in the opinion of the
             investigator.

          -  Women who are pregnant or nursing.
Clinical trial NCT02164539 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: ff, umec, vi
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)C3=CC=CO3)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  COPD with evidence of an asthmatic component as demonstrated by spirometry,
             reversibility and current therapy at screening as follows:

               -  Post-bronchodilator morning (AM) FEV1 >=50% and <=80% of the predicted normal
                  value at Visit 1

               -  Pre- and post-bronchodilator FEV1/FVC ratio <0.7.

               -  Demonstrated reversibility by >=12% and >=200 mL increase in FEV1 following
                  albuterol at Visit 1.

               -  A need for regular controller therapy (i.e., inhaled corticosteroids alone or in
                  combination with a long-acting beta-agonist or leukotriene modifier, etc.) for a
                  minimum of 12 weeks prior to Visit 1.

          -  Outpatient subjects who are smokers or non-smokers.

        Exclusion Criteria:

          -  History of life-threatening respiratory event within the last 5 years.

          -  Unresolved respiratory infection

          -  Recent Severe COPD or Asthma Exacerbation

          -  Risk factors for pneumonia

          -  Hospitalization for pneumonia within 3 months

          -  Concurrent respiratory disease other than chronic obstructive pulmonary disease or
             asthma.

          -  Other uncontrolled condition or disease state that, in the opinion of the
             investigator, would put the safety of the subject at risk through study participation
             or would confound the interpretation of the efficacy results if the condition/disease
             exacerbated during the study.

          -  Viral hepatitis or HIV

          -  Current or chronic history of liver disease, known hepatic or biliary abnormalities

          -  Drug or milk protein allergy

          -  Administration of prescription or over-the-counter medication that would significantly
             affect the course of COPD or asthma, or interact with study drug

          -  Subjects with lung volume reduction surgery within 12 months prior to screening.

          -  Use of long-term oxygen therapy (LTOT)

          -  Requirement for nebulized therapy

          -  Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks

          -  Unstable or life-threatening cardiac disease

          -  Abnormal and clinically significant 12-Lead Electrocardiogram (ECG) finding

          -  Diseases preventing the use of anticholinergics
Clinical trial NCT02167217 (phase 2, status: completed)
Conditions: duchenne muscular dystrophy
ICD codes: G71.01
Drugs: prednisolone
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          1. Appropriate degree of weakness for age, creatine kinase greater than 20 times the
             upper limit of normal, and genetic mutation known to be causative for Duchenne
             muscular dystrophy .

          2. Appropriate degree of weakness for age, creatine kinase greater than 20 times the
             upper limit of normal and genetic or biopsy confirmation of Duchenne muscular
             dystrophy in a primary relative (e.g. brother or maternal uncle).

          3. De-identified, genetic studies will be reviewed by collaborator Kevin Flanigan, MD
             prior to enrollment of subjects.

          4. Age at entry: one month through 30 months.

        Exclusion Criteria:

          -  Prior treatment with corticosteroids
Clinical trial NCT02169180 (phase 2, status: completed)
Conditions: lymphoma, mantle-cell
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: ibrutinib
SMILES: NC1=NC=NC2=C1C(=NN2[C@@H]1CCCN(C1)C(=O)C=C)C1=CC=C(OC2=CC=CC=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of mantle cell lymphoma ( MCL) must include morphology and expression of
             either cyclin D1 in association with one B-cell marker (for example, cluster of
             differentiation [CD] CD19, CD20, or paired box [PAX5]) or evidence of t(11;14) as
             assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase
             chain reaction (PCR)

          -  Received at least 1 prior lines of therapy for MCL (separate lines of therapy are
             defined as single or combination therapies that are either separated by disease
             progression or by a greater than 6-month treatment-free interval)

          -  At least 1 measurable site of disease according to the Revised Response Criteria for
             Malignant Lymphoma (that is, the site of disease must be greater than 1.5 centimeter
             [cm] in the long axis regardless of short axis measurement or greater than 1.0 cm in
             the short axis regardless of long axis measurement, and clearly measurable in 2
             perpendicular dimensions)

          -  Have documented failure to achieve at least partial response (PR) with, or documented
             disease progression after, the most recent anti-MCL treatment regimen

          -  Eastern Cooperative Oncology Group performance status score of 0 or 1

        Exclusion Criteria:

          -  Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer
             antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation
             therapy within 3 weeks, or major surgery within 4 weeks of the first dose of study
             drug

          -  Prior treatment with ibrutinib or other Bruton's Tyrosine Kinase (BTK) inhibitors

          -  More than 5 prior lines of therapy for MCL (separate lines of therapy are defined as
             single or combination therapies that are either separated by disease progression or by
             a greater than 6-month treatment-free interval)

          -  Known central nervous system (CNS) lymphoma

          -  Woman who is pregnant, breast-feeding, or planning to become pregnant within 1 month
             after the last dose of study drug or is a man who plans to father a child while
             enrolled in this study or within 3 months after the last dose of study drug
Clinical trial NCT02169505 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: brentuximab vedotin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          1. Patients with CD30 positive Hodgkin Lymphoma (HL) or anaplastic large cell lymphoma
             (ALCL) that have undergone allogeneic or haploidentical SCT in the past 60 days
             (matched related or matched unrelated donors only).

          2. Age 18 to 65 years.

          3. Performance status: Zubrod 0-1 or Karnofsky 80-100.

          4. Serum creatinine < 1.5 mg/dL or creatinine clearance greater than or equal to 40
             cc/min as defined by MDRD method from National Kidney Disease Education Program
             (NKDEP).

          5. Serum direct bilirubin < 1.5 mg/dL (unless Gilbert's syndrome).

          6. SGPT < 200 IU/L unless related to patient's malignancy.

          7. Evidence of neutrophil and platelet engraftment, defined as platelet count equal or
             greater than 50,000 mm3 independent of platelet transfusion and ANC equal or greater
             to 1000 without growth factor support for at least 5 days.

          8. Patients with previous exposure to brentuximab pre-transplant are eligible for the
             study.

        Exclusion Criteria:

          1. Pregnancy or breast-feeding (women of childbearing potential, any female who has
             experienced menarche and who has not undergone surgical sterilization or is
             post-menopausal with a positive serum pregnancy test.

          2. Presence of steroid-refractory acute graft-versus-host disease (GVHD).

          3. Patients that underwent allogeneic transplantation as a treatment of graft failure.

          4. Dual refractory CMV reactivation to foscarnet and ganciclovir or evidence of CMV
             disease.
Clinical trial NCT02173301 (phase 2, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: xp23829 400 mg qd, xp 23829 800 mg qd, xp23829 400 mg bid, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Male and female subjects, age ≥ 18.

          2. Stable, moderate-to-severe plaque-type psoriasis diagnosed for at least 6 months prior
             to randomization (no morphology changes or significant flares of disease activity in
             the last 6 months in the opinion of the investigator).

          3. Severity of disease meeting all of the following three criteria prior to
             randomization:

               1. Psoriasis Area and Severity Index (PASI) score of 12 or greater

               2. Total Body Surface Area (BSA) affected by plaque psoriasis of 10% or greater

               3. Static Physician's Global Assessment (sPGA) score of 3 or greater

          4. Must be a candidate for phototherapy and/or systemic therapy for psoriasis.

        Exclusion Criteria:

          1. Subjects with current inverse, erythrodermic, predominantly guttate, or pustular
             psoriasis.

          2. Subjects with current drug-induced or drug-exacerbated psoriasis.

          3. Subjects with moderate-to-severe psoriatic arthritis of any type; and subjects with
             mild psoriatic arthritis, who require systemic disease-modifying therapy.

          4. Subjects with unstable or significant illness, including the presence of laboratory
             abnormalities at screening that in the opinion of the investigator would place the
             subject at unacceptable risk if he/she were to participate in the study.

          5. Any skin condition (e.g. eczema) which confounds the ability to interpret data from
             the study.

          6. Treatment with a topical anti-psoriatic therapy within 14 days prior to randomization
             (including topical steroids, topical vitamin A or D analog preparations, tacrolimus,
             pimecrolimus, or anthralin).

          7. Phototherapy or prolonged sun exposure or use of ultraviolet (UV) light sources within
             28 days of randomization.

          8. Use of investigational or approved biologic treatments that are known to affect
             psoriasis, such as adalimumab, etanercept, golimumab or infliximab within 12 weeks of
             randomization and ustekinumab within 24 weeks of randomization.

          9. Use of systemic medications (non-biologics) that are known to affect psoriasis
             (including but not limited to oral corticosteroids, cyclosporine, methotrexate,
             lithium, and beta-adrenergic blockers) within 4 weeks of randomization, or 5
             half-lives, whichever is longer.

         10. Prior treatment with Dimethyl Fumarate (Fumaderm® or Tecfidera®) or any other Fumaric
             Acid Ester (FAE) containing products.

         11. Have failed (due to inadequate response) more than 3 approved systemic agents for the
             treatment of psoriasis.